Aymeric Couturier: Lessons from the TRACK Trial on Anticoagulation in Advanced CKD
Aymeric Couturier, Nephrologist at the American Hospital, Member of the Clinical Research Committee of SFNDT – Francophone Society of Nephrology, Dialysis, and Transplantation shared on LinkedIn:
”Anticoagulation and Advanced CKD: Negative Results from the TRACK Study Published in JAMA
In 1,458 patients with stage 4–5 CKD or on dialysis, low-dose rivaroxaban (2.5 mg twice daily) did not reduce major cardiovascular events compared with placebo after a median follow-up of 1.7 years:
Primary endpoint:
HR 1.09 (95% CI 0.87–1.36; p=0.46)
Cardiovascular events:
22.6% vs 20.7%
Major bleeding:
- significant increase with rivaroxaban
- HR 1.51 (95% CI 1.02–2.22; p=0.04)
The trial was terminated early due to futility and suspicion of ‘net harm.’
These results contrast with those of COMPASS and VOYAGER-PAD, likely due to:
- the pro-inflammatory and pro-thrombotic profile of patients with advanced CKD,
- the lack of combination with aspirin,
- a high rate of treatment discontinuation (~28%).
- 42.1% of all deaths were sudden cardiac deaths.
Important clinical message:
Antithrombotic strategies validated in the general cardiovascular population cannot be directly extrapolated to patients with advanced kidney disease or on dialysis.
These results also raise the question of anticoagulation in atrial fibrillation among dialysis patients, an area where randomized clinical trials remain limited.”
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 13:29Factor XI Deficiency and the Challenge of Unpredictable Bleeding – EHC
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI